175 related articles for article (PubMed ID: 36799168)
1. FBXO30 functions as a tumor suppressor and an E3 ubiquitin ligase for hZIP1‑mediated HIF‑1α degradation in renal cell carcinoma.
Yuan Y; Liu Z; Li B; Gong Z; Piao C; Liu Z; Zhang Z; Dong X
Int J Oncol; 2023 Mar; 62(3):. PubMed ID: 36799168
[TBL] [Abstract][Full Text] [Related]
2. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
3. A HIF1α-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism.
Liu R; Feng Y; Deng Y; Zou Z; Ye J; Cai Z; Zhu X; Liang Y; Lu J; Zhang H; Luo Y; Han Z; Zhuo Y; Xie Q; Hon CT; Liang Y; Wu CL; Zhong W
J Exp Clin Cancer Res; 2021 Jun; 40(1):188. PubMed ID: 34098990
[TBL] [Abstract][Full Text] [Related]
4. hZIP1 that is down-regulated in clear cell renal cell carcinoma is negatively associated with the malignant potential of the tumor.
Dong X; Kong C; Zhang Z; Liu X; Zhan B; Chen Z; Shi D
Urol Oncol; 2014 Aug; 32(6):885-92. PubMed ID: 24878177
[TBL] [Abstract][Full Text] [Related]
5. HIF1α is not a target of 14q deletion in clear cell renal cancer.
Shenoy N
Sci Rep; 2020 Oct; 10(1):17642. PubMed ID: 33077781
[TBL] [Abstract][Full Text] [Related]
6. The role of HIF1α in renal cell carcinoma tumorigenesis.
Gudas LJ; Fu L; Minton DR; Mongan NP; Nanus DM
J Mol Med (Berl); 2014 Aug; 92(8):825-36. PubMed ID: 24916472
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1-mediated translation of HIF1α in clear cell renal cell carcinoma.
Zhao P; Deng Y; Wu Y; Guo Q; Zhou L; Yang X; Wang C
FASEB J; 2021 Feb; 35(2):e21160. PubMed ID: 33150667
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF-κB pathway inactivation.
Gui D; Dong Z; Peng W; Jiang W; Huang G; Liu G; Ye Z; Wang Y; Xu Z; Fu J; Luo S; Zhao Y
Cancer Med; 2021 Jun; 10(11):3674-3688. PubMed ID: 33973730
[TBL] [Abstract][Full Text] [Related]
9. USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer.
Xie H; Zhou J; Liu X; Xu Y; Hepperla AJ; Simon JM; Wang T; Yao H; Liao C; Baldwin AS; Gong K; Zhang Q
Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2119854119. PubMed ID: 36037364
[TBL] [Abstract][Full Text] [Related]
10. HACE1 blocks HIF1α accumulation under hypoxia in a RAC1 dependent manner.
Turgu B; Zhang F; El-Naggar A; Negri GL; Kogler M; Tortola L; Johnson F; Ng T; Li A; Yapp D; Lockwood W; Martinez D; Maris JM; Daugaard M; Penninger JM; Hughes CS; Sorensen PH
Oncogene; 2021 Mar; 40(11):1988-2001. PubMed ID: 33603169
[TBL] [Abstract][Full Text] [Related]
11. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
12. Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway.
Xu Z; Chen S; Liu R; Chen H; Xu B; Xu W; Chen M
Mol Cancer; 2022 Jul; 21(1):146. PubMed ID: 35840930
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial E3 ubiquitin ligase 1 promotes autophagy flux to suppress the development of clear cell renal cell carcinomas.
Yuan Y; Li X; Xu Y; Zhao H; Su Z; Lai D; Yang W; Chen S; He Y; Li X; Liu L; Xu G
Cancer Sci; 2019 Nov; 110(11):3533-3542. PubMed ID: 31489722
[TBL] [Abstract][Full Text] [Related]
14. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
15. F-box protein FBXO30 mediates retinoic acid receptor γ ubiquitination and regulates BMP signaling in neural tube defects.
Cheng X; Pei P; Yu J; Zhang Q; Li D; Xie X; Wu J; Wang S; Zhang T
Cell Death Dis; 2019 Jul; 10(8):551. PubMed ID: 31320612
[TBL] [Abstract][Full Text] [Related]
16. The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma.
Mizutani A; Koinuma D; Seimiya H; Miyazono K
Oncogene; 2016 Jul; 35(27):3514-23. PubMed ID: 26522722
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
18. Silent information regulator 2 promotes clear cell renal cell carcinoma progression through deacetylation and small ubiquitin-related modifier 1 modification of glucose 6-phosphate dehydrogenase.
Ni Y; Yang Z; Agbana YL; Bai H; Wang L; Yang L; Yi Z; Cheng J; Zhang Q; Kuang Y; Zhu Y
Cancer Sci; 2021 Oct; 112(10):4075-4086. PubMed ID: 34310804
[TBL] [Abstract][Full Text] [Related]
19. TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
[TBL] [Abstract][Full Text] [Related]
20. RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma.
Liu Y; Cheng G; Song Z; Xu T; Ruan H; Cao Q; Wang K; Bao L; Liu J; Zhou L; Liu D; Yang H; Chen K; Zhang X
Int J Oncol; 2019 Sep; 55(3):645-656. PubMed ID: 31364727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
